Barclays analyst Matthew Bouley maintains AZEK Co (NYSE:AZEK) with a Overweight and raises the price target from $28 to $33.
Neuronetics Launches Innovations To NeuroStar Advanced Therapy’s Proprietary TrakStar Platform
Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders,
